Market Intelligence, Clinical Progress, and High-Purity Reagents for Retinal Degeneration and Gene Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CNGB1/GARP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CNGB1 (GARP Domain) Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CNGB1 Products |
| Gene Delivery | CNGB1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CNGB1 Products |
| Benchmark Ab | Anti-CNGB1 Recombinant Antibody Recombinant positive control. |
View CNGB1 Products |
| Validator | CNGB1 siRNA Set For knockdown verification. |
View CNGB1 Products |
| Related Target A | CNGA1 Co-assembles with CNGB1 to form functional rod cyclic nucleotide-gated channels. |
View CNGA1 Products |
| Related Target B | CNGA3 Homologous cone channel subunit; essential for counter-screening and selectivity assays. |
View CNGA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane protein folding & heteromeric assembly | Lentiviral ORF delivery for stable cell line generation to preserve native conformation |
| Subfamily counter-screening (CNGB1 vs. CNGB3) | Homolog panel proteins strictly verified by sequence and mass spectrometry |
| Lack of clinical-grade positive controls | Recombinant benchmark antibodies included for assay standardization |
| Off-target validation and cross-reactivity | Sequence-verified GARP-specific domain proteins for precise epitope mapping |
Live CNGB1/GARP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CNGB1 therapeutics is intensifying, with major players shifting focus from traditional small molecules to gene therapy (AAV-mediated gene replacement). CNGB1 mutations cause autosomal recessive Retinitis Pigmentosa (RP45), a progressive blinding disease. As first-generation gene therapies reach clinical evaluation, the next wave of R&D is targeting efficient dual-vector delivery systems to bypass AAV packaging limits and developing high-fidelity channel-modulation assays.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | LMU Munich, ViGeneron, LK-001 | Retinitis Pigmentosa (RP45) | Transduction & expression validation (Need CNGB1 Lentivirus / ORF) |
| Small Molecule Modulators | Academic Institutes, Biotech | Channelopathies, Retinal Diseases | Ion channel functional screening (Need CNGA1/CNGB1 co-expression cell lines) |
| Antibody Therapies | Diagnostic & Research Developers | Retinal Biomarkers, Research Tools | Epitope specificity mapping (Need Recombinant GARP domain proteins) |